Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2020-11-26 Remuneration Information
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Grant of Share Options & PDMR dealing
Remuneration Information Classification · 1% confidence The document is an official announcement filed via RNS (RNS Number : 5422G) dated November 26, 2020. The primary content details the 'Grant of Share Options & PDMR dealing' involving Directors and Persons Discharging Managerial Responsibilities (PDMRs). This type of filing, which reports transactions by insiders (directors/executives) regarding their holdings or options, specifically aligns with the definition of Director's Dealing (DIRS). While it involves share options (which could relate to CAP or SHA), the focus on PDMR notification and transaction details makes DIRS the most precise classification. It is not a full financial report (10-K, IR) or a general announcement of a report (RPA).
2020-11-26 English
Conversion of Convertible Security
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement released via RNS (RNS Number : 2066G) on November 24, 2020. The content details the conversion of a convertible security into new ordinary shares, the resulting increase in the total number of shares in issue, and the anticipated admission to trading. This type of announcement, which reports on changes to capital structure (share issuance/conversion) and regulatory compliance (DTR notification), fits best under Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the core event is the issuance of new shares following a debt/security conversion, SHA is highly relevant. However, the document also functions as a general regulatory disclosure via RNS. Given the specific nature of reporting share issuance/capital changes, SHA is more precise than the general RNS fallback. It is not an ER, IR, 10-K, or a simple announcement of a report (RPA). I will classify it as SHA due to the focus on the allotment and admission of New Ordinary Shares.
2020-11-24 English
Conversion of Convertible Security
Capital/Financing Update Classification · 1% confidence The document is a formal announcement released via RNS (RNS Number: 0867G) on November 23, 2020. The content details the conversion of a convertible security into new ordinary shares, resulting in an increase in the total issued share capital (247,716,315 Ordinary Shares). This action directly relates to changes in the company's capital structure and share issuance. This fits the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core event is the issuance of new shares following a debt/security conversion, SHA is the most precise fit, as it covers new share issues. It is not an earnings release (ER), a full annual report (10-K), or a management discussion (MDA). It is a specific corporate action announcement.
2020-11-23 English
Conversion of Convertible Security
Capital/Financing Update Classification · 1% confidence The document announces the 'Conversion of Convertible Security' resulting in the issuance of 1,430,510 new ordinary shares. It details the mechanics of the share issuance, the expected admission to trading, and updates the total shares in issue for regulatory disclosure purposes (DTR). This action directly relates to changes in the company's capital structure and financing arrangements (conversion of debt/security into equity). This fits best under 'Capital/Financing Update' (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2020-11-23 English
Update : FDA confirms 4 Dec for Type ‘A’ meeting
Legal Proceedings Report Classification · 1% confidence The document is identified by the header 'RNS Number' and contains an update regarding a Type 'A' meeting with the FDA concerning a Phase 3 trial for a drug (Lupuzor™). It is a short announcement providing an update on regulatory/clinical progress and includes contact information typical of a regulatory news service release. The presence of 'RNS Number' and the concluding boilerplate text about RNS (the news service of the London Stock Exchange) strongly indicates this is a general regulatory announcement. Since it is an update on clinical/regulatory progress rather than a full financial report (10-K, IR) or a specific insider trade (DIRS), the most appropriate classification is the general regulatory filing category, RNS.
2020-11-20 English
FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
Regulatory Filings Classification · 1% confidence The document is a short announcement from ImmuPharma PLC updating the market on a confirmed meeting date (December 4, 2020) with the FDA regarding the Phase 3 trial guidance for their drug Lupuzor™. It provides key details about the meeting's purpose (seeking guidance on study design and conditional approval) and states that a further update will follow the meeting outcome. The text is brief (under 5,000 characters) and functions as a timely market disclosure about an ongoing regulatory/clinical process, rather than a full financial report (like 10-K or IR) or a formal shareholder vote result. Since it is a specific, non-financial regulatory update concerning clinical trials and FDA interaction, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially as a Legal/Regulatory update (LTR), but RNS is the broader fallback for such specific, non-periodic corporate news that isn't explicitly covered elsewhere. Given the nature of updating on FDA interactions, RNS is the most appropriate general regulatory disclosure code.
2020-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.